Clinical Trials, FDA, Therapeutics Corey Hubbard Clinical Trials, FDA, Therapeutics Corey Hubbard

The Undruggable Enemy: Why This Tiny Vaccine is Making Cancer Cells Sweat (And Investors Cheer)

In the ongoing war against cancer, some enemies are famously difficult to hit. One such stubborn target is a mutated protein known as KRAS (mutant-Kirsten rat sarcoma), which plays a significant role in the pathology of disease. For decades, developing therapies to target KRAS has been extraordinarily challenging, primarily because the protein lacks readily available binding pockets

Read More